Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young… - Blood, The Journal …, 2020 - ashpublications.org
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young, A Marshall… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young… - …, 2020 - researchinformation.amsterdamumc …
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
[HTML][HTML] Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young, A Marshall… - Blood, 2020 - Elsevier
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
FI Mulder, FTM Bosch, AM Young, A Marshall… - Blood, 2020 - europepmc.org
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young, A Marshall… - Blood, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Direct oral anticoagulants (DOACs) are an
emerging treatment option for patients with cancer and acute venous thromboembolism …
emerging treatment option for patients with cancer and acute venous thromboembolism …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young, A Marshall… - …, 2020 - mayoclinic.elsevierpure.com
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, F Bosch, AM Young, A Marshall, RD McBane… - Blood, 2020 - wrap.warwick.ac.uk
Direct oral anticoagulants (DOACs) are an emerging treatment option for cancer patients
with acute venous thromboembolism (VTE), but studies have reported inconsistent results …
with acute venous thromboembolism (VTE), but studies have reported inconsistent results …